COVID-19 vaccines
Covid-19: Bangladesh registers 43 more deaths; positivity rate hits 11.03%
As Coronavirus-related deaths and infections keep growing in Bangladesh again, the country recorded 43 more deaths in the past 24 hours till Saturday morning.
Besides, 1,447 new cases were registered during the period, taking the country's caseload to 809,314.
With the latest death toll, the total number of fatalities rose to 12,801.
The daily infection rate climbed to 11.03% from Friday's 10.40% while the mortality rate remained static at 1.58%, according to the Directorate General of Health Services (DGHS).
The new cases were detected after testing 13,115 samples.
Dhaka and Rajshahi divisions saw the highest fatalities during the period with 12 deaths each while Chattogram division witnessed eight deaths, Khulna five, Rangpur three, Mymensingh two and Sylhet one.
Of the deceased, 30 were men while 13 women.
Of them, one was below 10 years, one in his 20s, five are 30 years old, two of 40, 13 are of 50 old and 21 are above 60 years.
READ: 1st USAID consignment of Covid-19 response relief on way to Bangladesh
However, 749,425 patients have recovered so far, keeping the country’s recovery rate at 92.60%.
Bangladesh reported its first Covid cases on March 8 last year and the first death on the 18th of that month.
Bangladesh records 34 more Covid deaths; positivity rate crosses 10%
As the administration of the first dose of the vaccine remains suspended in Bangladesh since April 26, the country continues to battle Covid-19, logging 1,887 new cases after testing 18,151 samples until Friday morning.
The new number took the country's caseload to 807,867. Also, the daily infection rate rose to 10.40% from Thursday's 9.94% while the mortality rate remained static at 1.58%, according to the Directorate General of Health Services (DGHS).
Meanwhile, the country confirmed 34 more deaths during the same period, raising the total number of fatalities to 12,758.
Dhaka division saw the highest fatalities during the period with the death of nine people while Chattogram witnessed six deaths, Rajshahi, Khulna, and Rangpur five each, Sylhet three and Barishal one.
READ: Covid-19: Govt to vaccinate 25 lakh people each month
However, 747,758 patients have recovered so far since the country reported its first Covid cases on March 8 last year and the first death on the 18th of that month.
Correlation between death rate, cases observed
To get an accurate measure of death rate, the number of infected people should be used as the denominator and the deceased as the numerator – both of which occurred and ended within a specified time, Dr AM Zakir Hussain, former director of the Institute of Epidemiology Disease Control and Research, told UNB.
"But for a disease like Covid-19, which still rages on, the rate should be considered in reference to a specific and relevant time. A recent assessment showed that the highest number of deaths occurred 14 days after the highest number of Covid-19 cases – a situation that still prevails in Bangladesh and India. So, the current method for estimating death rate is not accurate," he said.
What’s test positivity?
The Covid-19 positivity rate indicates, among other things, the number of people showing clinical features of the disease or the percentage of individuals suffering from the disease. Such estimation has two errors, Dr Zakir said.
READ: Covid-19: Bangladesh logs 30 more deaths, 1,687 new infections
"One, an RT-PCR test, based on the present method of sample collection, misses about one-third of the actual cases. Two, when more than 20 cycles of diagnostic procedures are repeated even a single virus in a sample would show a positive result, which, however, will not indicate that the person who gave the sample will transmit the infection to others or that they will come down with the disease. An RT-PCR test shows positive results even when the virus is dead," he added.
Lockdown in districts
Due to the recent rise in Covid infections in frontier districts, district administrations have imposed lockdowns in Rajshahi, Khulna, Satkhira and parts of Naogaon districts to curb the transmission of the virus.
The district administrations have been given the authority to enforce lockdowns in their areas if the Covid-19 situation worsens.
US unveils strategy for global vaccine sharing with Bangladesh, India on list
The US Administration has unveiled its strategy for global vaccine sharing through COVAX, keeping Bangladesh and India on the list.
The Biden-Harris Administration on Thursday announced an allocation plan for the first 25 million doses to be shared globally.
Approximately 7 million doses will be shared in Asia covering countries and entities, including Bangladesh, India, Nepal, Pakistan, Sri Lanka, Afghanistan, the Maldives, Malaysia, the Philippines, Vietnam, Indonesia, Thailand, Laos, Papua New Guinea, Taiwan, and the Pacific Islands, according to White House.
As they continue to fight the Covid-19 pandemic at home and work to end the pandemic worldwide, US President Joe Biden has promised that the United States will be an arsenal of vaccines for the world.
Also read: COVAX Facility: Japan to provide 30mn vaccine doses to other countries
To do that, the administration will pursue several additional measures beyond their robust funding for COVAX: Donating from the US vaccine supply to the world and encouraging other nations to do the same, working with US manufacturers to increase vaccine production for the rest of the world, and help more countries expand their own capacity to produce vaccines, including through support for global supply chains.
This vaccine strategy is a vital component of our overall global strategy to lead the world in the fight to defeat Covid-19, including emergency public health assistance and aid to stop the spread and building global public health capacity and readiness to beat not just this pandemic, but the next one.
The administration announced its framework for sharing at least 80 million US vaccine doses globally by the end of June and the plan for the first 25 million doses.
The United States will share vaccines in service of ending the pandemic globally.
Also read: Vaccine maker Serum seeks indemnity protection in India
The administration announced its framework for sharing these 80 million US vaccine doses worldwide.
Close to committing $1 billion to Moderna for Covid-19 booster shot: Cipla
Seeking fast-track approvals to bring Moderna’s single-dose Covid-19 booster vaccine in India expeditiously, Cipla has requested the government for indemnification and exemptions from price capping, bridging trials and basic customs duty, while stating that it is close to committing over ₹1 billion as advance to the US major, sources said on Monday, reports Hindustan Times.
Commending the government for its efforts to increase the vaccine availability in the country for achieving effective protection against Covid-19, the Indian pharma giant has said its discussions with Moderna on the Covid-19 booster vaccine are nearing finalisation and for that, they are seeking the “partnership and support of the government to make this programme successful”.
Requesting the government to provide confirmation on four critical points --- exemption from price restriction, indemnification, bridging trial waiver and basic customs duty exemption, Cipla has said such an assurance will help make this significant financial commitment of more than USD 1 billion (over ₹7,250 crore) advance to Moderna for its booster vaccine in India, sources privy to the development said.
Cipla’s latest communication to the government, dated May 29, follows a high-level meeting held recently during which it was discussed that Moderna has proposed to launch a single-dose vaccine for the Indian market, for which, they were in discussion with Cipla and other Indian companies.
It was also discussed in that meeting that orders for supply of the vaccine in 2022 may be placed with Moderna expeditiously and that Cipla has evinced interest to procure 50 million doses from Moderna for 2022. It was also suggested that Cipla may be asked to submit their specific requests to the government on their request for a “confirmation from the Government of India in respect of stability in regulatory requirements/policy regime” and a decision on that can be taken thereafter expeditiously.
Taking the matter forward, Cipla has now written to the government, “It is imperative Cipla brings Moderna booster vaccines to India urgently, having immediately made available the largest portfolio of Covid-19 drugs amongst Indian pharmaceutical companies, including the state-of-the-art antibody cocktail of Casirivimab and Imdevimab.”
Stating that Moderna’s vaccine has been rated at the highest efficacy with least side effects, Cipla has told the government that it needs assurance to include Moderna booster vaccine under the Liberalised Pricing and Accelerated National Covid-19 Vaccination Strategy, announced in April and made effective from May 1.
Bangladesh sees rise in Covid infections; 41 more die
Amid the growing trend in both the Coronavirus infections and fatalities, Bangladesh logged 41 more deaths, pushing up the death toll to 12,660.
Besides, health authorities detected 1,765 new cases after testing 18,250 samples during the period.
The country’s daily death record remained below 40 since May 25 while it stayed below 50 since May 9.
With the new cases, the total caseload rose to 8,02,305, said a handout of the Directorate General of Health Services (DGHS).
The daily infection rate slightly increased to 9.47 percent from Monday’s 9.41 percent while the mortality rate remained static at 1.58 percent.
The country has so far tested 59,65,763 samples.
Read:Covid: WHO renames UK and other variants with Greek letters
The DGHS handout says 92.50% of the people infected till now have recovered, including 1,779 who tested negative during the period.
Bangladesh reported its first Coronavirus cases on March 8 last year and the first death on the 18th of that month.
Johnson & Johnson asks high court to void $2B talc verdict
Johnson & Johnson is asking for Supreme Court review of a $2 billion verdict in favor of women who claim they developed ovarian cancer from using the company’s talc products.
The case features an array of high-profile attorneys, some in unusual alliances, including former independent counsel Kenneth Starr, who is representing the women who sued Johnson & Johnson. The nation’s largest business groups are backing the company, and a justice’s father also makes an appearance because of his long association with the trade group for cosmetics and personal care products.
Read:Apple brings CEO Tim Cook to court in defense of app store
The court could say as soon as Tuesday whether it will get involved.
At the root, Johnson & Johnson argues that the company didn’t get a fair shake in a trial in state court in Missouri that resulted in an initial $4.7 billion verdict in favor of 22 women who used talc products and developed ovarian cancer.
A state appeals court cut more than half the money out of the verdict and eliminated two of the plaintiffs, but otherwise upheld the outcome in a trial in which lawyers for both sides presented dueling expert testimony about whether the company’s talc products contain asbestos and asbestos-laced talc can cause ovarian cancer.
The jury found for the women on both points, after which Judge Rex M. Burlison wrote that evidence at the trial showed “particularly reprehensible conduct on the part of Defendants.”
The evidence, Burlison wrote, included that the company knew there was asbestos in products aimed at mothers and babies, knew of the potential harm and “misrepresented the safety of these products for decades.”
Nine of the women have died from ovarian cancer, lawyers for the plaintiffs said
Johnson & Johnson denies that its talc products cause cancer and it called the verdict in the Missouri trial “at odds with decades of independent scientific evaluations confirming Johnson’s Baby Powder is safe, is not contaminated by asbestos and does not cause cancer.” The company also is the maker of one of three COVID-19 vaccines approved for use in the United States.
Health concerns about talcum powders have prompted thousands of U.S. lawsuits by women who claim asbestos in the powder caused their cancer. Talc is a mineral similar in structure to asbestos, which is known to cause cancer, and they are sometimes obtained from the same mines. The cosmetics industry in 1976 agreed to make sure its talc products do not contain detectable amounts of asbestos.
Last year, a U.S. government-led analysis of 250,000 women found no strong evidence linking baby powder with ovarian cancer in the largest analysis to look at the question, though the study’s lead author called the results “very ambiguous.”
Read:Asian shares mixed after retreat on Wall Street
The findings were called “overall reassuring” in an editorial published with the study in January 2020 in the Journal of the American Medical Association. The study wasn’t definitive but more conclusive research probably isn’t feasible because a dwindling number of women use powder for personal hygiene, the editorial said.
A few months later, the company announced it would stop selling its iconic talc-based Johnson’s Baby Powder in the U.S. and Canada, citing declining demand driven by what it called misinformation about health concerns.
The disputed link between cancer and talc is not really a part of the high court case. Instead, the company said it should have not been forced to defend itself in one trial against claims by women from 12 states, differing backgrounds and with varying histories of using Johnson & Johnson products containing talc.
The $1.6 billion in punitive damages is out of line and should be reduced, the company also argued in a brief that was written by Neal Katyal, a Washington lawyer who aligns with progressive causes and also represents corporate clients. Katyal, who was the acting top Supreme Court lawyer for a time in the Obama administration, declined an on-the-record interview.
The U.S. Chamber of Commerce and trade associations for manufacturers, insurers and the pharmaceutical industry are among the business organizations backing Johnson & Johnson’s appeal.
Tiger Joyce, president of the American Tort Reform Association, pointed to how long it took the trial judge to read the jury its instructions as an indication of how unfair the trial was to Johnson & Johnson.
“When a defendant is facing a case where it takes over five hours for the judge to read the jury instructions to the jury, you just have to ask yourself what are we doing here,” said Joyce, whose group generally backs limits on liability lawsuits.
Starr said in an interview with The Associated Press that none of Johnson & Johnson’s legal arguments is worth the court’s time. “As the jury found and as every judge to review this six-week trial record has concluded, Johnson & Johnson’s conduct over decades was reprehensible,” Starr said.
In addition to Starr, other members of the women’s legal team are former Attorney General John Ashcroft and Washington lawyers David Frederick and Tom Goldstein, frequent advocates before the Supreme Court.
Justice Brett Kavanaugh worked for Starr when he investigated the affair between President Bill Clinton and Monica Lewinsky, which led to Clinton’s impeachment.
Read:Oprah and CNN: AT&T is merging media business with Discovery
Another name that pops up in some documents in the case is E. Edward Kavanaugh, who was the longtime president of the Cosmetic, Toiletry and Fragrance Association and is the justice’s father.
Kavanaugh’s group fought efforts to list talc as a carcinogen or attach warning labels to talc products. Kavanaugh is retired and the group now is called the Personal Care Products Council.
Ethicists contacted by the AP said they haven’t seen anything that would warrant the justice having to step aside from the case.
Already, one justice almost certainly won’t take part. Justice Samuel Alito reported last year that he owned $15,000 to $50,000 in Johnson & Johnson stock. Federal law prohibits judges from sitting on cases in which they have financial interest.
Bangladesh records lowest Covid deaths in over two months
Bangladesh logged 17 more Covid-related deaths in 24 hours until Wednesday morning, the lowest number in 68 days.
The country saw 16 Covid-19 deaths on March 18 last.
Besides, 1,497 new cases were recorded taking the total caseload to 7,93,693, said a handout of the Directorate General of Health Services (DGHS).
The Covid-19 positivity rate declined to 9.11 percent from Tuesday’s 10.08 percent while the mortality rate remained static at 1.57 percent, the handout said.
Health authorities recorded the new cases after testing 16,434 samples in the last 24 hours.
With 1,056 recoveries in the past 24 hours, the country's recovery rate now stands at 92.46.
As of now, 7,33,866 people have recovered from the disease.
Eight of the 17 deaths recorded today are from Chattogram and five are from Dhaka divisions.
Also read: Bangladesh braces for worst Covid outbreak by June-end: Experts
One each died in Khulna, Barishal, Mymensingh and Sylhet divisions.
The country so far carried out 58,71,353 sample tests since reporting its first coronavirus cases on March 8 last year and the first death on March 18, 2020.
Bangladesh begins administering 1st dose of Chinese vaccine
Bangladesh on Tuesday began administering the first dose of Chinese Sinopharm vaccine, marking a major turning point in its fight against Covid-19 pandemic.
Health Minister Zahid Maleque inaugurated the inoculation programme at Dhaka Medical College and Hospital.
On May 12, Bangladesh received 5 lakh China’s Sinopharm Covid-19 vaccine doses, donated by the Chinese government.
Since the outbreak of the pandemic last year, China and Bangladesh have been supporting and assisting each other in their fight against the pandemic.
China has donated and is donating vaccine doses to 80 developing countries with urgent needs, and has provided support under COVAX for the emergency use of vaccines in developing countries.
Also read: Process to procure vaccine from China at final stage: FM
China has fulfilled its commitment to make the Covid-19 vaccine a global public good with practical actions, promoted the fair distribution of global vaccines and made China’s contribution to the realisation of vaccine accessibility and affordability in developing countries.
China says it will continue to make joint efforts with Bangladesh to make positive contributions to Bangladesh’s endeavour of protecting human lives and fight to win the battle against the pandemic, and together to build an even closer community of shared future and health for mankind.
Covid-19 vaccines: Commonwealth health ministers demand equal access for everyone
Commonwealth health ministers have called for swift and equal access to Covid-19 vaccines for everyone around the world.
They expressed deep concern over the stark gaps in access and delivery of doses, especially in poor countries, and called for "fair and transparent" pricing for the vaccine in a joint statement Friday on behalf of the 54 Commonwealth member countries.
Only 0.3% of the life-saving vaccine doses have been administered in 29 poor countries. About 84% of shots have been given in high and upper-middle-income countries.
Commonwealth Secretary-General Patricia Scotland said: "The science is clear: vaccination works and is the clear and only sustainable route out of this pandemic for the whole world."
"The rise of new variants shows that until everyone is safe no one is safe. No plan to tackle this virus will work until everyone agrees to work together."
"We must talk with each other to move away from some stockpiling vaccines, while many low-middle income countries still do not have access to the much-needed vaccine supplies for the vulnerable populations in their countries. So, cooperation to develop a global immunisation plan to deliver equal access to vaccines must be a top priority," Patricia added.
Vaccine equity
The Commonwealth health ministers appreciated the global vaccine equity initiative "COVAX" and encouraged all partners to support government efforts on boosting vaccine confidence and immunisation drives.
Recognising the acute gaps in research and development of new tests, vaccines and therapies in the Commonwealth, they stressed enhanced collaboration with scientists, academics and business leaders.
Speaking at the meeting, the World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus said: "Vaccines are reducing severe disease and death in countries that are fortunate enough to have them in sufficient quantities, and early results suggest that vaccines might also drive down transmission."
"The shocking global disparity in access to vaccines remains one of the biggest risks to ending the pandemic. We seek the support of the Commonwealth in solving the global vaccine crisis by funding the ACT Accelerator, advocating for greater sharing of technology, know-how and intellectual property, and sharing doses with COVAX."
The ministers further backed a potential treaty on the fight against pandemics and a Commonwealth mechanism to share and distribute extra medical supplies such as ventilators and medicines.
They called on the heads of government to allocate resources for strengthening health systems, especially through primary healthcare, towards attaining universal health coverage.
Maintaining essential health services
New data shows 60 immunisation campaigns for other health threats are now suspended in 50 countries due to Covid-19. Such delays could cause significant avoidable mortality.
Disruptions to HIV/AIDS services, for instance, could lead to five thousand excess deaths globally.
So, the ministers committed to keeping essential health services running and sustaining the gains made towards tackling threats such as malaria, HIV/AIDS, avoidable blindness and non-communicable diseases while dealing with an influx of Covid-19 cases.
In their statement, they further voiced their support for a common framework for sovereign debt treatments, cooperation with the WHO and improved compliance with the International Health Regulations for preventing the spread of disease.
This is the second time that Commonwealth health ministers met virtually for their annual gathering due to the Covid-19 pandemic.
The meeting, hosted by the Commonwealth Secretariat, took place on 20 and 21 May.
Covid vaccine: China to send additional 6 lakh doses as gift
China is preparing a the second batch of 600,000 doses of its COVID-19 vaccine to Bangladesh.
The announcement came Friday, just nine days after the arrival of the first batch of 500,000 doses of Sinopharm vaccine as a gift.
China says the move fully reflects that it attaches great importance to the friendly relations between the two countries.
Chinese State Councilor and Foreign Minister Wang Yi had a phone conversation with Foreign Minister Dr AK Abdul Momen on Friday to this end.
Read Bangladesh, China, others call for avoiding vaccine nationalism
At the request of Bangladesh, it was announced that China would handover the second batch of 600,0000 vaccine doses to Bangladesh.
China pays close attention to the latest situation of the epidemic in Bangladesh, the Chinese Embassy in Dhaka said.
At this critical time in Bangladesh’s fight against the epidemic, China is concerned about the urgent need for vaccinating its Bangladeshi friends, to help the overcomes the huge demand for domestic and foreign orders and the shortage of vaccine supply, it said.
The arrival of the second batch vaccine will definitely help the Bangladeshi government and people build a strong line of defense against the epidemic, China said.
Also read: Govt approves proposal to import Sinofarm vaccine
In the future, China is willing to provide necessary support for Bangladesh and South Asian countries to fight the epidemic, deepen anti-epidemic cooperation with Bangladesh, and effectively protect the health and security of their citizens.
The Chinese Foreign Minister assured of providing all kinds of support to ensure continuation of "stable supply" of COVID vaccines to Bangladesh.
Dr Momen requested his Chinese counterpart to take an initiative for coproduction of vaccines in Bangladesh.
The Chinese Foreign Minister said they will encourage the Chinese companies to go for coproduction of vaccines with Bangladesh.
Read WHO team working with Chinese vaccine producers ahead of potential emergency use: WHO director-general
He said China keeps up its support with Malaysia, Turkey, Brazil and the United Arab Emirates on vaccine coproduction.